Sandeep Gupta, MD
Psychiatry · Wilmington, DENPI 1972577005
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$587
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$449
- Otsuka America Pharmaceutical, Inc.$418
- Neurocrine Biosciences, Inc.$339
- Johnson & Johnson$337
- Alkermes, Inc.$231
- plus $2K from 23 others
Across 61 payments — averaging $352.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$22K
What the payments were for
- Food & beverage$4,17098%
- Education$742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $587 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $449 |
| Otsuka America Pharmaceutical, Inc. | 25 | $418 |
| Neurocrine Biosciences, Inc. | 12 | $339 |
| Johnson & Johnson | 14 | $337 |
| Alkermes, Inc. | 11 | $231 |
| Sunovion Pharmaceuticals Inc. | 13 | $230 |
| Bausch Health US, LLC | 11 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $197 |
| Axsome Therapeutics, Inc. | 5 | $136 |
| Vanda Pharmaceuticals Inc. | 5 | $133 |
| Lundbeck LLC | 7 | $108 |
| Supernus Pharmaceuticals, Inc. | 5 | $108 |
| Idorsia Pharmaceuticals US Inc | 5 | $95 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $91 |
| Ironshore Pharmaceuticals Inc. | 4 | $73 |
| Shire North American Group Inc | 3 | $63 |
| Jazz Pharmaceuticals Inc. | 3 | $59 |
| Tris Pharma Inc | 3 | $51 |
| Neos Therapeutics, LP | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $29 |
| Livanova USA, Inc. | 1 | $26 |
| Corium, LLC | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| OWP Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$4,244 in reported general payments places this provider in the 90th percentile of 114 psychiatry providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 88 | $181,433 |
| SpravatoEsketamine Hcl | 116 | $140,547 |
| IngrezzaValbenazine Tosylate | 12 | $102,675 |
| RexultiBrexpiprazole | 31 | $77,684 |
| CaplytaLumateperone Tosylate | 18 | $30,914 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $24,040 |
| VyvanseLisdexamfetamine Dimesylate | 47 | $18,293 |
| Lurasidone Hcl | 24 | $14,314 |
| TrintellixVortioxetine Hydrobromide | 17 | $13,168 |
| Lisdexamfetamine Dimesylate | 36 | $10,438 |
| Bupropion XlBupropion Hcl | 305 | $10,271 |
| Duloxetine Hcl | 201 | $5,833 |
| Alprazolam | 527 | $5,159 |
| Aripiprazole | 168 | $5,114 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 154 | $4,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $587 | $181,43388 claims |
| Johnson & JohnsonSpravato | $337 | $140,547116 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $339 | $102,67512 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $418 | $77,68431 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $197 | $31,46164 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $449 | $30,91418 claims |
| Alkermes, Inc.Lybalvi | $231 | $24,04015 claims |
| Eisai Inc.Dayvigo | $29 | $3,63111 claims |
| Almatica Pharma LLCSertraline Hcl | $23 | $1,718140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 114 psychiatry providers in Delaware.
Other psychiatry in Wilmington
- Ranganathan RamWilmington$202K
- Manisha WadhwaWilmington$89K
- Vishesh AgarwalWilmington$46K
- Kathlyn RowenWilmington$5K
- Nana BerikashviliWilmington$3K
- Karl McIntoshWilmington$2K
- Fawzia HasanWilmington$2K
- Jose CapiroWilmington$1K
- Imran TrimziWilmington$1K
- Chandrakala KathiravanWilmington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.